GON Stock Chart & Stats
€1.29
€0.02(1.64%)
At close: 4:00 PM EDT
€1.29
€0.02(1.64%)
Day’s Range― - ―
52-Week Range€0.92 - €1.63
Previous CloseN/A
Volume0.00
Average Volume (3M)2.30K
Market Cap
€739.91M
Enterprise Value€807.52
Total Cash (Recent Filing)€300.85M
Total Debt (Recent Filing)€122.14M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume2,342
30 Day Avg. Volume2,304
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.81Price Target Upside195.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€204.84M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceStrong quarterly and first-half revenue growth, together with reiterated full-year guidance, indicates expanding commercial traction for RYTELO. Continued execution against these targets could establish a more durable product-revenue base and improve operating leverage as adoption develops.
Commercial Account ExpansionGrowth in demand, prescribing accounts, and earlier-line patient starts shows that RYTELO is broadening beyond an initial customer base. A wider prescriber footprint can support recurring treatment utilization and strengthen the product’s commercial position over the next several quarters.
Operating Leverage And Capital StructureExpense discipline relative to revenue growth suggests improving operating leverage, while very low leverage and substantial liquidity provide flexibility for commercialization and clinical investment. This combination gives Geron more capacity to execute its strategy without relying solely on debt.
Bears Say
High Cash BurnDeeply negative operating and free cash flow shows that the current business is not yet self-funding. Persistent cash consumption can require external financing or use of existing reserves, potentially limiting strategic flexibility and creating dilution risk if commercialization does not scale quickly.
Continued Net LossesGeron remains materially unprofitable even as revenue and operating margins improve. Continued net losses leave earnings dependent on future scale and expense control, making the company more vulnerable if product adoption, reimbursement, or development outcomes fall short of expectations.
Clinical And Regulatory UncertaintyPotential changes to the IMpactMF interim analysis introduce uncertainty around readout timing and the regulatory pathway for a key pipeline opportunity. Although the base-case final overall-survival timeline is unchanged, evolving requirements could delay or complicate value creation.
Geron News
GON FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was €0.92 and its highest was €1.63 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is €739.91M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 11, 2026 which is in 47 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of -€0.008 by -€0.01.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -€0.017 in its last earnings report, missing expectations of -€0.008. Following the earnings report the stock price went up 9.79%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in DE:GON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.81 (195.32% Upside)
€3.81 (195.32% Upside)
Blogger Sentiment
Bullish
DE:GON Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all DE:GON earnings summariesGON Stock 12 Month Forecast
Average Price Target
€3.81
▲(195.32% Upside)